The top Medicare official tasked with heading CMS’ drug price negotiation group signaled the agency might loosen its proposed requirement to restrict drug companies from disclosing details about the negotiation process.
Published: Jan 20, 2021
CLARKSVILLE, Md., Jan. 20, 2021 (GLOBE NEWSWIRE)
Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel pharmacotherapy: NNI-362 to allosterically stimulate neural regeneration in human cultures and
in vivo models of aging and disease. This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers.
The short report in the Stem Cell Research & Therapy journal https://doi.org/10.1186/s13287-020-02126-3 entitled “Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease”, describes the phenotypic screen used by Neuronascent to discover NNI-362 and details the